Double Helix Biotechnology Dev. has been acquired by Interpublic Group of Companies
Double Helix Bio-Technology Development Ltd. (Double Helix), a leading, global provider of market research and market access services to the pharmaceutical and medical device industries, has been sold to McCann Health, owned by The Interpublic Group of Companies Inc. Financial details of this transaction have not been disclosed.
Founded by Dr Wayne Phillips and based in London, Double Helix not only specializes in the established markets of the US and Europe, but also focuses on emerging markets, providing clients with a truly global perspective. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients. Dr Phillips will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.
McCann Health is a part of McCann Worldgroup, the largest marketing communications agency network in the world, and is a leading healthcare agency network owned by The Interpublic Group of Companies Inc.
Oaklins Cavendish, based in the UK, acted as financial advisor to the seller.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn moreNiscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn more